Paracetamol for pain in adults

Drugs for chronic pain

“…13 Owing to safety concerns, particularly with modified release preparations, there have been policy changes limiting access to certain paracetamol formulations in some countries. 14 Oral NSAIDs also remain popular with ~11.5 million prescriptions in England in 2018 (26% reduction since 2013). 14 There is a role for oral NSAIDs for certain chronic pain conditions, for example, they provide modest benefit for pain in chronic LBP 15 and are recommended in existing NICE guidelines for LBP.…”

National Poison Center Calls Before vs After Availability of High-Dose Acetaminophen (Paracetamol) Tablets in Switzerland

“…Nevertheless, the wide utilization of 1000-mg acetaminophen in Switzerland is concerning considering the ongoing debate regarding the evidence of effectiveness. 7 , 8 , 27 , 28 A 2011 meta-analysis 29 found that acetaminophen has a marginal benefit compared with placebo in acute pain, and NICE recently released guidance removing acetaminophen from the list of recommended treatments for chronic pain management because of a lack of effectiveness and increased risk of harm. 12 In addition, it has been shown that acetaminophen users were more likely to remedicate early, thereby suggesting a lack of effectiveness and a potential for unintentional poisoning.…”

“…In many Western countries, acetaminophen poisoning is the leading cause of liver failure, 5 and researchers have identified that prolonged exposure to high daily doses can increase the risk of liver failure and death. 6 Thus, in light of the limited evidence of a clinical benefit for musculoskeletal conditions, headache and migraine, or dental pain, 7 , 8 , 9 , 10 concerns regarding the benefit-risk profile of acetaminophen have been raised. 11 In August 2020, the National Institute for Health and Care Excellence (NICE) released draft guidance on chronic pain management, in which acetaminophen (paracetamol) is no longer recommended because of its unfavorable benefit-risk profile.…”

“… 1 , 19 , 20 This is despite limited evidence of the benefit of acetaminophen in pain management 8 and accumulating safety concerns with high doses, including hepatoxicity, major cardiovascular events, bleeding, and upper gastrointestinal complications. 6 , 8 In Switzerland, acetaminophen is available as 500-mg tablets OTC and with prescription, and as of October 2003, 1000-mg tablets are available with a prescription. Therefore, we sought to characterize and examine the number of acetaminophen-related poisoning reports in Switzerland before and after the introduction of the 1000-mg tablets using quasi-experimental interrupted time series (ITS) analysis.…”

Photoluminescence as a Valuable Tool in the Optical Characterization of Acetaminophen and the Monitoring of Its Photodegradation Reactions

“…Acetaminophen (AC) is an active compound of different drugs marketed under the name of Paracetamol, Theraflu, Coldrex, Parasinus, Algopirin, and so on. The therapeutic effects for which AC is administered are: (i) the reduction of headaches during migraines [ 1 ]; (ii) the diminution of kidney stone-induced pain [ 2 ]; (iii) osteoarthritis which involves the pain at the hip, knee and hands [ 3 ]; (iv) the cutting down of the pain resulting after dental procedures [ 4 ]; (v) fighting fever [ 5 ] and recently in coronavirus disease (Covid-19) [ 6 ]. The most important adverse effects of AC reported until now consist of the generation of liver damage [ 7 , 8 ].…”